Swiss National Bank Buys 2,500 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)

Swiss National Bank raised its holdings in shares of Arcus Biosciences, Inc. (NYSE:RCUS – Get Rating) by 2.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 104,496 shares of the company’s stock after acquiring an additional 2,500 shares during the period. Swiss National Bank owned approximately 0.14% of Arcus Biosciences worth $2,161,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. BlackRock Inc. raised its position in shares of Arcus Biosciences by 9.9% during the 3rd quarter. BlackRock Inc. now owns 8,928,228 shares of the company’s stock valued at $233,559,000 after acquiring an additional 805,534 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Arcus Biosciences by 4.1% in the 3rd quarter. Vanguard Group Inc. now owns 4,457,184 shares of the company’s stock valued at $116,600,000 after buying an additional 173,854 shares during the period. State Street Corp grew its holdings in shares of Arcus Biosciences by 61.3% in the 2nd quarter. State Street Corp now owns 4,435,849 shares of the company’s stock valued at $112,404,000 after buying an additional 1,685,930 shares during the period. PFM Health Sciences LP grew its holdings in shares of Arcus Biosciences by 1.1% in the 3rd quarter. PFM Health Sciences LP now owns 3,383,233 shares of the company’s stock valued at $88,505,000 after buying an additional 36,775 shares during the period. Finally, Goldman Sachs Group Inc. grew its holdings in shares of Arcus Biosciences by 295.3% in the 2nd quarter. Goldman Sachs Group Inc. now owns 974,132 shares of the company’s stock valued at $24,685,000 after buying an additional 727,692 shares during the period. Institutional investors own 72.97% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on RCUS shares. TheStreet lowered shares of Arcus Biosciences from a “c-” rating to a “d” rating in a report on Tuesday, February 28th. Citigroup reduced their target price on shares of Arcus Biosciences from $42.00 to $40.00 in a research note on Thursday, March 9th. Finally, Mizuho reaffirmed a “buy” rating and issued a $51.00 target price on shares of Arcus Biosciences in a research note on Friday, March 17th. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $41.33.

Arcus Biosciences Price Performance

Arcus Biosciences stock opened at $17.50 on Friday. The firm has a 50-day moving average of $18.10 and a 200-day moving average of $21.32. Arcus Biosciences, Inc. has a one year low of $15.70 and a one year high of $36.13. The company has a market cap of $1.28 billion, a price-to-earnings ratio of -4.55 and a beta of 0.88.

Arcus Biosciences (NYSE:RCUS – Get Rating) last issued its earnings results on Tuesday, May 9th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.06) by ($0.03). The firm had revenue of $25.00 million during the quarter, compared to the consensus estimate of $22.47 million. Arcus Biosciences had a negative net margin of 233.41% and a negative return on equity of 41.22%. The firm’s revenue for the quarter was up 38.9% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.96) earnings per share. As a group, sell-side analysts expect that Arcus Biosciences, Inc. will post -4.43 earnings per share for the current year.

Insider Activity

In other Arcus Biosciences news, COO Jennifer Jarrett sold 8,729 shares of the stock in a transaction dated Thursday, March 16th. The shares were sold at an average price of $16.81, for a total value of $146,734.49. Following the transaction, the chief operating officer now directly owns 406,217 shares of the company’s stock, valued at approximately $6,828,507.77. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 13.80% of the stock is owned by insiders.

About Arcus Biosciences

(Get Rating)

Arcus Biosciences, Inc engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.